These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 21417957)
41. Management of dyslipidemia in the high-risk patient. Stein EA Am Heart J; 2002 Dec; 144(6 Suppl):S43-50. PubMed ID: 12486415 [TBL] [Abstract][Full Text] [Related]
42. Statin drug interactions and related adverse reactions. Bellosta S; Corsini A Expert Opin Drug Saf; 2012 Nov; 11(6):933-46. PubMed ID: 22866966 [TBL] [Abstract][Full Text] [Related]
43. Ezetimibe plus fenofibrate: a new combination therapy for the management of mixed hyperlipidaemia? Farnier M Expert Opin Pharmacother; 2007 Jun; 8(9):1345-52. PubMed ID: 17563268 [TBL] [Abstract][Full Text] [Related]
44. Tolerability of statin-fibrate and statin-niacin combination therapy in dyslipidemic patients at high risk for cardiovascular events. Taher TH; Dzavik V; Reteff EM; Pearson GJ; Woloschuk BL; Francis GA Am J Cardiol; 2002 Feb; 89(4):390-4. PubMed ID: 11835917 [TBL] [Abstract][Full Text] [Related]
45. Simvastatin interactions with other drugs. Florentin M; Elisaf MS Expert Opin Drug Saf; 2012 May; 11(3):439-44. PubMed ID: 22416996 [TBL] [Abstract][Full Text] [Related]
46. Combination of fenofibrate with non-statin drug regimens. Agouridis AP; Filippatos TD; Derdemezis CS; Mikhailidis DP; Elisaf MS Curr Pharm Des; 2010 Oct; 16(30):3401-16. PubMed ID: 20819059 [TBL] [Abstract][Full Text] [Related]
47. Fixed-dose combination therapy with statins: strengths, limitations, and clinical and regulatory considerations. Hennekens CH Am J Cardiovasc Drugs; 2008; 8(3):155-60. PubMed ID: 18533736 [TBL] [Abstract][Full Text] [Related]
48. Statin-fibrate combination: therapy for hyperlipidemia: a review. Wierzbicki AS; Mikhailidis DP; Wray R; Schacter M; Cramb R; Simpson WG; Byrne CB Curr Med Res Opin; 2003; 19(3):155-68. PubMed ID: 12814127 [TBL] [Abstract][Full Text] [Related]
49. Myopathy induced by statin-ezetimibe combination: Evaluation of potential risk factors. Brahmachari B; Chatterjee S Indian J Pharmacol; 2015; 47(5):563-4. PubMed ID: 26600650 [TBL] [Abstract][Full Text] [Related]
50. Fenofibric acid for hyperlipidemia. Saurav A; Kaushik M; Mohiuddin SM Expert Opin Pharmacother; 2012 Apr; 13(5):717-22. PubMed ID: 22404421 [TBL] [Abstract][Full Text] [Related]
52. ETC-1002 (Bempedoic acid) for the management of hyperlipidemia: from preclinical studies to phase 3 trials. Ruscica M; Banach M; Sahebkar A; Corsini A; Sirtori CR Expert Opin Pharmacother; 2019 May; 20(7):791-803. PubMed ID: 30810432 [TBL] [Abstract][Full Text] [Related]
53. Effective use of combination lipid therapy. Vasudevan AR; Jones PH Curr Atheroscler Rep; 2006 Jan; 8(1):76-84. PubMed ID: 16455018 [TBL] [Abstract][Full Text] [Related]
54. Statin intolerance: now a solved problem. Sikka P; Kapoor S; Bindra VK; Sharma M; Vishwakarma P; Saxena KK J Postgrad Med; 2011; 57(4):321-8. PubMed ID: 22120862 [TBL] [Abstract][Full Text] [Related]
55. Meta-analysis of safety of the coadministration of statin with fenofibrate in patients with combined hyperlipidemia. Guo J; Meng F; Ma N; Li C; Ding Z; Wang H; Hou R; Qin Y Am J Cardiol; 2012 Nov; 110(9):1296-301. PubMed ID: 22840347 [TBL] [Abstract][Full Text] [Related]
56. A safety look at currently available statins. Moghadasian MH Expert Opin Drug Saf; 2002 Sep; 1(3):269-74. PubMed ID: 12904142 [TBL] [Abstract][Full Text] [Related]
57. Long-term statin safety and efficacy in secondary prevention: can combination therapy improve outcomes? Wascher TC Atheroscler Suppl; 2003 Dec; 4(5):11-6. PubMed ID: 14980230 [TBL] [Abstract][Full Text] [Related]